Hims Hers Health Inc is trading 6.9% up at $34.09 following a bullish note from Barclays highlighting significant reacceleration in the company’s weight loss segment.
- Barclays raised its price target from $29 to $39 with an Overweight rating, citing proprietary data that shows strong momentum in the company’s GLP-1 business.
- The updated price target implies over 34% upside, further fueling a multi-day rally that has seen the stock climb from $26.82 on June 12.
- Investor optimism remains high as the company's expansion into the GLP-1 market continues to drive growth expectations and positive analyst sentiment.